Creating a better vaccine for tuberculosis
Official title: Development of an Optimized Adjuvanted TB Vaccine
Funded at University of Montana · NIH-11196784 · Data updated 2026-11-12
This study is looking for a better tuberculosis (TB) vaccine by trying out different ingredients that help boost the immune system, so we can find the best way to protect people at risk of TB.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Montana NIH-funded |
| Lab location | 1 site (Missoula, United States) |
| Project start | September 30, 2021 |
| Project end | September 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $358,674 |
| NIH project number | 75N93019C00045-P00023-9999-4 |
| Project ID | NIH-11196784 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for tuberculosis, including those with compromised immune systems or living in areas with high TB prevalence.
✕Less likely to help
Patients who are not at risk for tuberculosis or those who have already been vaccinated with an effective TB vaccine may not benefit from this research.
What this research studies
This research focuses on developing an improved tuberculosis (TB) vaccine by testing various adjuvants, which are substances that enhance the body's immune response to the vaccine. Researchers will formulate experimental vaccines using different adjuvants and evaluate their effectiveness in generating a strong immune response. By comparing these formulations, the study aims to identify which adjuvant works best in protecting against TB infection or disease. This could lead to a more effective vaccine that provides better protection for individuals at risk of TB.
Why it matters
Potential benefit: If successful, this research could lead to a more effective TB vaccine, significantly reducing the incidence of tuberculosis.
How similar studies have gone: Previous research has shown promise in optimizing vaccine adjuvants, indicating that this approach could lead to significant advancements in vaccine efficacy.
Where this research is happening
-
University of Montana
Missoula, United States Active
Researchers
- Principal investigator: Evans, Jay — University of Montana
- Study coordinator: Evans, Jay
Related research
Other NIH-funded projects on the same topics.
-
Doula support to improve mood and anxiety health for rural mothers
A rural-focused program tests whether birth doulas can boost confidence, support, and maternal health for new mothers with mood and anxiety concerns.
-
Telehealth exercise program to help rural breast cancer survivors fight fatigue
A telehealth exercise program is being tested to reduce cancer-related fatigue in rural breast cancer survivors.
-
Behavioral cough suppression and capsaicin for refractory chronic cough
A multi-site study will test how a behavioral therapy for stopping cough works alone and with capsaicin to help people with stubborn chronic cough.
-
Rocky Mountain translational hub to bring discoveries to patients
A Montana hub will speed up turning university discoveries into real health tools that help people, especially in remote states.
-
RDCD Core: Design, Compliance, and Data Management for Montana translational research
A dedicated core helps Montana researchers plan ethical, well-designed studies using big health data and EHRs to advance clinical and translational science.
-
Community Engagement and Outreach Core for Montana Health Research
A state-wide effort to support clinicians and researchers in partnering with communities to design and share health research that reflects local needs.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.